Apolipoprotein B-100–Containing Lipoprotein Metabolism in Subjects With Lipoprotein Lipase Gene Mutations

OBJECTIVE—We investigated the impact of lipoprotein lipase (LPL) gene mutations on apolipoprotein B (apoB)-100 metabolism. METHODS AND RESULTS—We studied 3 subjects with familial LPL deficiency; 14 subjects heterozygous for the LPL gene mutations Gly188Glu, Trp64Stop, and Ile194Thr; and 10 control s...

Full description

Saved in:
Bibliographic Details
Published inArteriosclerosis, thrombosis, and vascular biology Vol. 32; no. 2; pp. 459 - 466
Main Authors Ooi, Esther M.M., Russell, Betsy S., Olson, Eric, Sun, Sam Z., Diffenderfer, Margaret R., Lichtenstein, Alice H., Keilson, Leonard, Barrett, P. Hugh R., Schaefer, Ernst J., Sprecher, Dennis L.
Format Journal Article
LanguageEnglish
Published Philadelphia, PA American Heart Association, Inc 01.02.2012
Lippincott Williams & Wilkins
Subjects
Online AccessGet full text
ISSN1079-5642
1524-4636
1524-4636
DOI10.1161/ATVBAHA.111.238493

Cover

Loading…
Abstract OBJECTIVE—We investigated the impact of lipoprotein lipase (LPL) gene mutations on apolipoprotein B (apoB)-100 metabolism. METHODS AND RESULTS—We studied 3 subjects with familial LPL deficiency; 14 subjects heterozygous for the LPL gene mutations Gly188Glu, Trp64Stop, and Ile194Thr; and 10 control subjects. Very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and low-density lipoprotein (LDL)-apoB-100 kinetics were determined in the fed state using stable isotope methods and compartmental modeling. Compared with controls, familial LPL deficiency had markedly elevated plasma triglycerides and lower VLDL-apoB-100 fractional catabolic rate (FCR), IDL-apoB-100 FCR, VLDL-to-IDL conversion, and VLDL-apoB-100 production rate (P<0.01). Compared with controls, Gly188Glu had higher plasma triglyceride and VLDL- and IDL-apoB-100 concentrations and lower VLDL- and IDL-apoB-100 FCR (P<0.05). Plasma triglycerides were not different, but IDL-apoB-100 concentration and production rate and VLDL-to-IDL conversion were lower in Trp64Stop compared with controls (P<0.05). No differences between controls and Ile194Thr were observed. CONCLUSION—Our results confirm that hypertriglyceridemia is a key feature of familial LPL deficiency. This is due to impaired VLDL- and IDL-apoB-100 catabolism and VLDL-to-IDL conversion. Single-allele mutations of the LPL gene result in modest to elevated plasma triglycerides. The changes in plasma triglycerides and apoB-100 kinetics are attributable to the effects of the LPL genotype.
AbstractList We investigated the impact of lipoprotein lipase (LPL) gene mutations on apolipoprotein B (apoB)-100 metabolism.OBJECTIVEWe investigated the impact of lipoprotein lipase (LPL) gene mutations on apolipoprotein B (apoB)-100 metabolism.We studied 3 subjects with familial LPL deficiency; 14 subjects heterozygous for the LPL gene mutations Gly188Glu, Trp64Stop, and Ile194Thr; and 10 control subjects. Very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and low-density lipoprotein (LDL)-apoB-100 kinetics were determined in the fed state using stable isotope methods and compartmental modeling. Compared with controls, familial LPL deficiency had markedly elevated plasma triglycerides and lower VLDL-apoB-100 fractional catabolic rate (FCR), IDL-apoB-100 FCR, VLDL-to-IDL conversion, and VLDL-apoB-100 production rate (P<0.01). Compared with controls, Gly188Glu had higher plasma triglyceride and VLDL- and IDL-apoB-100 concentrations and lower VLDL- and IDL-apoB-100 FCR (P<0.05). Plasma triglycerides were not different, but IDL-apoB-100 concentration and production rate and VLDL-to-IDL conversion were lower in Trp64Stop compared with controls (P<0.05). No differences between controls and Ile194Thr were observed.METHODS AND RESULTSWe studied 3 subjects with familial LPL deficiency; 14 subjects heterozygous for the LPL gene mutations Gly188Glu, Trp64Stop, and Ile194Thr; and 10 control subjects. Very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and low-density lipoprotein (LDL)-apoB-100 kinetics were determined in the fed state using stable isotope methods and compartmental modeling. Compared with controls, familial LPL deficiency had markedly elevated plasma triglycerides and lower VLDL-apoB-100 fractional catabolic rate (FCR), IDL-apoB-100 FCR, VLDL-to-IDL conversion, and VLDL-apoB-100 production rate (P<0.01). Compared with controls, Gly188Glu had higher plasma triglyceride and VLDL- and IDL-apoB-100 concentrations and lower VLDL- and IDL-apoB-100 FCR (P<0.05). Plasma triglycerides were not different, but IDL-apoB-100 concentration and production rate and VLDL-to-IDL conversion were lower in Trp64Stop compared with controls (P<0.05). No differences between controls and Ile194Thr were observed.Our results confirm that hypertriglyceridemia is a key feature of familial LPL deficiency. This is due to impaired VLDL- and IDL-apoB-100 catabolism and VLDL-to-IDL conversion. Single-allele mutations of the LPL gene result in modest to elevated plasma triglycerides. The changes in plasma triglycerides and apoB-100 kinetics are attributable to the effects of the LPL genotype.CONCLUSIONSOur results confirm that hypertriglyceridemia is a key feature of familial LPL deficiency. This is due to impaired VLDL- and IDL-apoB-100 catabolism and VLDL-to-IDL conversion. Single-allele mutations of the LPL gene result in modest to elevated plasma triglycerides. The changes in plasma triglycerides and apoB-100 kinetics are attributable to the effects of the LPL genotype.
We investigated the impact of lipoprotein lipase (LPL) gene mutations on apolipoprotein B (apoB)-100 metabolism. We studied 3 subjects with familial LPL deficiency; 14 subjects heterozygous for the LPL gene mutations Gly188Glu, Trp64Stop, and Ile194Thr; and 10 control subjects. Very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and low-density lipoprotein (LDL)-apoB-100 kinetics were determined in the fed state using stable isotope methods and compartmental modeling. Compared with controls, familial LPL deficiency had markedly elevated plasma triglycerides and lower VLDL-apoB-100 fractional catabolic rate (FCR), IDL-apoB-100 FCR, VLDL-to-IDL conversion, and VLDL-apoB-100 production rate (P<0.01). Compared with controls, Gly188Glu had higher plasma triglyceride and VLDL- and IDL-apoB-100 concentrations and lower VLDL- and IDL-apoB-100 FCR (P<0.05). Plasma triglycerides were not different, but IDL-apoB-100 concentration and production rate and VLDL-to-IDL conversion were lower in Trp64Stop compared with controls (P<0.05). No differences between controls and Ile194Thr were observed. Our results confirm that hypertriglyceridemia is a key feature of familial LPL deficiency. This is due to impaired VLDL- and IDL-apoB-100 catabolism and VLDL-to-IDL conversion. Single-allele mutations of the LPL gene result in modest to elevated plasma triglycerides. The changes in plasma triglycerides and apoB-100 kinetics are attributable to the effects of the LPL genotype.
OBJECTIVE—We investigated the impact of lipoprotein lipase (LPL) gene mutations on apolipoprotein B (apoB)-100 metabolism. METHODS AND RESULTS—We studied 3 subjects with familial LPL deficiency; 14 subjects heterozygous for the LPL gene mutations Gly188Glu, Trp64Stop, and Ile194Thr; and 10 control subjects. Very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and low-density lipoprotein (LDL)-apoB-100 kinetics were determined in the fed state using stable isotope methods and compartmental modeling. Compared with controls, familial LPL deficiency had markedly elevated plasma triglycerides and lower VLDL-apoB-100 fractional catabolic rate (FCR), IDL-apoB-100 FCR, VLDL-to-IDL conversion, and VLDL-apoB-100 production rate (P<0.01). Compared with controls, Gly188Glu had higher plasma triglyceride and VLDL- and IDL-apoB-100 concentrations and lower VLDL- and IDL-apoB-100 FCR (P<0.05). Plasma triglycerides were not different, but IDL-apoB-100 concentration and production rate and VLDL-to-IDL conversion were lower in Trp64Stop compared with controls (P<0.05). No differences between controls and Ile194Thr were observed. CONCLUSION—Our results confirm that hypertriglyceridemia is a key feature of familial LPL deficiency. This is due to impaired VLDL- and IDL-apoB-100 catabolism and VLDL-to-IDL conversion. Single-allele mutations of the LPL gene result in modest to elevated plasma triglycerides. The changes in plasma triglycerides and apoB-100 kinetics are attributable to the effects of the LPL genotype.
Author Sun, Sam Z.
Diffenderfer, Margaret R.
Sprecher, Dennis L.
Schaefer, Ernst J.
Olson, Eric
Barrett, P. Hugh R.
Russell, Betsy S.
Ooi, Esther M.M.
Lichtenstein, Alice H.
Keilson, Leonard
AuthorAffiliation From the Lipid Metabolism Laboratory (E.M.M.O., M.R.D., E.J.S.) and Cardiovascular Nutrition Laboratory (A.H.L.), Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA; Metabolic Research Centre, School of Medicine and Pharmacology (E.M.M.O., P.H.R.B.), and Faculty of Engineering, Computing and Mathematics (E.M.M.O., P.H.R.B.), University of Western Australia, Perth, Western Australia, Australia; Division of Digestive Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH (B.S.R.); Discovery Medicine, Cardiovascular-Urology Center of Excellence for Drug Discovery (CVU CEDD), GlaxoSmithKline, King of Prussia, PA (E.O., D.L.S.); Office of Compliance and Ethics, Archer Daniels Midland Company, Decatur, IL (S.Z.S.); Maine Center for Lipids and Cardiovascular Health, Portland, ME (L.K.)
AuthorAffiliation_xml – name: From the Lipid Metabolism Laboratory (E.M.M.O., M.R.D., E.J.S.) and Cardiovascular Nutrition Laboratory (A.H.L.), Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA; Metabolic Research Centre, School of Medicine and Pharmacology (E.M.M.O., P.H.R.B.), and Faculty of Engineering, Computing and Mathematics (E.M.M.O., P.H.R.B.), University of Western Australia, Perth, Western Australia, Australia; Division of Digestive Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH (B.S.R.); Discovery Medicine, Cardiovascular-Urology Center of Excellence for Drug Discovery (CVU CEDD), GlaxoSmithKline, King of Prussia, PA (E.O., D.L.S.); Office of Compliance and Ethics, Archer Daniels Midland Company, Decatur, IL (S.Z.S.); Maine Center for Lipids and Cardiovascular Health, Portland, ME (L.K.)
– name: 4 Discovery Medicine, CVU CEDD, GlaxoSmithKline, King of Prussia, PA, USA
– name: 2 Metabolic Research Centre, School of Medicine & Pharmacology, and Faculty of Engineering, Computing and Mathematics, University of Western Australia, Perth, Western Australia, Australia
– name: 1 Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA
– name: 3 Division of Digestive Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH, USA
– name: 6 Cardiovascular Nutrition Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA
– name: 5 Office of Compliance and Ethics, Archer Daniels Midland Company, Decatur, IL, USA
– name: Maine Center for Lipids and Cardiovascular Health, Portland, ME, USA
Author_xml – sequence: 1
  givenname: Esther
  surname: Ooi
  middlename: M.M.
  fullname: Ooi, Esther M.M.
  organization: From the Lipid Metabolism Laboratory (E.M.M.O., M.R.D., E.J.S.) and Cardiovascular Nutrition Laboratory (A.H.L.), Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA; Metabolic Research Centre, School of Medicine and Pharmacology (E.M.M.O., P.H.R.B.), and Faculty of Engineering, Computing and Mathematics (E.M.M.O., P.H.R.B.), University of Western Australia, Perth, Western Australia, Australia; Division of Digestive Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH (B.S.R.); Discovery Medicine, Cardiovascular-Urology Center of Excellence for Drug Discovery (CVU CEDD), GlaxoSmithKline, King of Prussia, PA (E.O., D.L.S.); Office of Compliance and Ethics, Archer Daniels Midland Company, Decatur, IL (S.Z.S.); Maine Center for Lipids and Cardiovascular Health, Portland, ME (L.K.)
– sequence: 2
  givenname: Betsy
  surname: Russell
  middlename: S.
  fullname: Russell, Betsy S.
– sequence: 3
  givenname: Eric
  surname: Olson
  fullname: Olson, Eric
– sequence: 4
  givenname: Sam
  surname: Sun
  middlename: Z.
  fullname: Sun, Sam Z.
– sequence: 5
  givenname: Margaret
  surname: Diffenderfer
  middlename: R.
  fullname: Diffenderfer, Margaret R.
– sequence: 6
  givenname: Alice
  surname: Lichtenstein
  middlename: H.
  fullname: Lichtenstein, Alice H.
– sequence: 7
  givenname: Leonard
  surname: Keilson
  fullname: Keilson, Leonard
– sequence: 8
  givenname: P. Hugh
  surname: Barrett
  middlename: R.
  fullname: Barrett, P. Hugh R.
– sequence: 9
  givenname: Ernst
  surname: Schaefer
  middlename: J.
  fullname: Schaefer, Ernst J.
– sequence: 10
  givenname: Dennis
  surname: Sprecher
  middlename: L.
  fullname: Sprecher, Dennis L.
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25489196$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/22095987$$D View this record in MEDLINE/PubMed
BookMark eNp9Ustu1TAQjVARfcAPsEDZIFYpfsbOBim9ghbpViwosLQcZ9LrNtcOtkPFjn_gD_kSXOUWWhYsbM_RnHNmNOPDYs95B0XxHKNjjGv8ur34fNKetRngY0Ila-ij4gBzwipW03ovx0g0Fa8Z2S8OY7xCCDFC0JNiP98Nb6Q4KK7byY928lPwCawrTyqM0K8fP1feJW2ddZfl-l76HJLusiBuy4w-zt0VmBTLLzZtHvByrCOUp-CgPJ-TTta7-LR4POgxwrPde1R8evf2YnVWrT-cvl-168owUcsK647VTBLEedPpvhsMGNPTru-Q6WVfC9GbGgT0fBgE5boXUnQYE9OJppcS6FHxZvGd5m4LvQGXgh7VFOxWh-_Ka6seZpzdqEv_TTFBGipoNni1Mwj-6wwxqa2NBsZRO_BzVA0WmAvJWWa-uF_qT427AWfCyx1BR6PHIWhnbPzL40w2uKkzTy48E3yMAQZl7DK23KEdFUbqdudqt_MMsFp2nqXkH-md-39FbBHd-DFBiNfjfANBbUCPaaNufwqtEa8IwgSRDKt8qKS_AZk_woA
CODEN ATVBFA
CitedBy_id crossref_primary_10_1210_er_2014_1062
crossref_primary_10_1371_journal_pone_0096482
crossref_primary_10_1146_annurev_nutr_071714_034338
crossref_primary_10_1161_ATVBAHA_115_305614
crossref_primary_10_1586_erc_12_21
crossref_primary_10_2337_dbi19_0007
crossref_primary_10_19161_etd_1209062
crossref_primary_10_1080_17512433_2018_1480368
crossref_primary_10_1186_s12944_020_01287_7
crossref_primary_10_1016_j_jacl_2018_03_093
crossref_primary_10_3343_alm_2017_37_4_355
crossref_primary_10_1093_cvr_cvt148
crossref_primary_10_1002_wsbm_1546
Cites_doi 10.1016/S0022-2275(20)37488-5
10.1161/circulationaha.109.875807
10.1016/0925-4439(92)90015-F
10.1016/S0022-2275(20)41328-8
10.1126/science.3461561
10.1016/S0022-2275(20)41340-9
10.1016/0021-9150(94)90129-5
10.1161/atvbaha.108.163931
10.1042/bst0210506
10.1073/pnas.95.23.13841
10.1016/j.pharmthera.2003.10.001
10.1172/JCI116074
10.1042/bj3470357
10.1093/aje/kwn235
10.1161/01.CIR.94.12.3239
10.1161/01.CIR.99.22.2901
10.1172/JCI116081
10.1194/jlr.M600292-JLR200
10.1111/j.1365-2362.1980.tb02090.x
10.1161/circulationaha.107.739888
10.1111/j.1432-1033.1993.tb17747.x
10.1194/jlr.R200015-JLR200
10.2337/diacare.19.6.629
10.1016/S0022-2275(20)41511-1
10.1194/jlr.M400152-JLR200
10.1073/pnas.74.11.4848
10.1172/JCI111644
10.1056/NEJM197806082982301
10.1161/01.CIR.96.6.1737
10.1016/S0021-9258(17)41822-9
10.1016/S0021-9258(18)52459-5
10.1056/NEJM198904203201607
10.1016/S0006-291X(72)80149-9
10.1172/JCI115229
10.1073/pnas.81.6.1839
10.1074/jbc.270.26.15747
10.1161/01.atv.0000203512.01007.3d
10.1016/j.cca.2005.12.038
10.1126/science.3823907
10.1172/JCI115114
10.1161/01.ATV.13.5.629
10.1016/S0022-2275(20)30146-2
ContentType Journal Article
Copyright 2012 American Heart Association, Inc.
2015 INIST-CNRS
Copyright_xml – notice: 2012 American Heart Association, Inc.
– notice: 2015 INIST-CNRS
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1161/ATVBAHA.111.238493
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1524-4636
EndPage 466
ExternalDocumentID PMC4729373
22095987
25489196
10_1161_ATVBAHA_111_238493
00043605-201202000-00038
Genre Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NHLBI NIH HHS
  grantid: 5R01-HL047496-02/3
– fundername: NHLBI NIH HHS
  grantid: R01 HL047496
GroupedDBID ---
.3C
.55
.GJ
.Z2
01R
0R~
1J1
23N
2WC
3O-
40H
4Q1
4Q2
4Q3
53G
5GY
5RE
5VS
71W
77Y
7O~
AAAAV
AAAXR
AAGIX
AAHPQ
AAIQE
AAMOA
AAMTA
AAQKA
AARTV
AASCR
AASOK
AAXQO
ABASU
ABBUW
ABDIG
ABJNI
ABPXF
ABQRW
ABVCZ
ABXVJ
ABZAD
ABZZY
ACCJW
ACDDN
ACEWG
ACGFS
ACGOD
ACILI
ACLDA
ACPRK
ACWDW
ACWRI
ACXJB
ACXNZ
ACZKN
ADBBV
ADFPA
ADGGA
ADHPY
ADNKB
AE3
AE6
AEETU
AENEX
AFBFQ
AFDTB
AFFNX
AFUWQ
AGINI
AHJKT
AHMBA
AHOMT
AHQNM
AHRYX
AHVBC
AIJEX
AINUH
AJCLO
AJIOK
AJNWD
AJNYG
AJZMW
AKCTQ
AKULP
ALKUP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AOQMC
AYCSE
BAWUL
BOYCO
BQLVK
BS7
C1A
C45
CS3
DIK
DIWNM
DUNZO
E.X
E3Z
EBS
EEVPB
EJD
ERAAH
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FL-
FRP
FW0
GNXGY
GQDEL
GX1
H0~
H13
HLJTE
HZ~
IKREB
IKYAY
IN~
IPNFZ
J5H
JF9
JG8
JK3
JK8
K8S
KD2
KMI
KQ8
L-C
L7B
N9A
N~7
N~B
N~M
O9-
OAG
OAH
OB2
OCUKA
ODA
OL1
OLG
OLH
OLU
OLV
OLY
OLZ
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OVIDH
OVLEI
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P-K
P2P
PQQKQ
PZZ
RAH
RIG
RLZ
S4R
S4S
T8P
TEORI
TR2
TSPGW
V2I
VVN
W3M
W8F
WOQ
WOW
X3V
X3W
X7M
XXN
XYM
YFH
ZGI
ZZMQN
AAYXX
ADGHP
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c4768-1ab464820559badbfceccd3bdb0cd8d677dc6e7ed5ff735ad787b112cb79d88e3
ISSN 1079-5642
1524-4636
IngestDate Thu Aug 21 13:45:04 EDT 2025
Fri Jul 11 07:34:47 EDT 2025
Mon Jul 21 06:07:26 EDT 2025
Mon Jul 21 09:13:39 EDT 2025
Tue Jul 01 02:21:47 EDT 2025
Thu Apr 24 22:56:07 EDT 2025
Fri May 16 03:46:47 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Human
apolipoproteins
Enzyme
Triacylglycerol lipase
Metabolic diseases
Lipids
Cardiovascular disease
Esterases
Hyperlipoproteinemia
Lipoprotein lipase
Lipoprotein
Metabolism
Carboxylic ester hydrolases
Vascular disease
Apolipoprotein B
lipases
Atherosclerosis
Hydrolases
gene mutations
Mutation
Dyslipemia
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c4768-1ab464820559badbfceccd3bdb0cd8d677dc6e7ed5ff735ad787b112cb79d88e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/4729373
PMID 22095987
PQID 917157854
PQPubID 23479
PageCount 8
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4729373
proquest_miscellaneous_917157854
pubmed_primary_22095987
pascalfrancis_primary_25489196
crossref_citationtrail_10_1161_ATVBAHA_111_238493
crossref_primary_10_1161_ATVBAHA_111_238493
wolterskluwer_health_00043605-201202000-00038
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2012-February
PublicationDateYYYYMMDD 2012-02-01
PublicationDate_xml – month: 02
  year: 2012
  text: 2012-February
PublicationDecade 2010
PublicationPlace Philadelphia, PA
PublicationPlace_xml – name: Philadelphia, PA
– name: United States
PublicationTitle Arteriosclerosis, thrombosis, and vascular biology
PublicationTitleAlternate Arterioscler Thromb Vasc Biol
PublicationYear 2012
Publisher American Heart Association, Inc
Lippincott Williams & Wilkins
Publisher_xml – name: American Heart Association, Inc
– name: Lippincott Williams & Wilkins
References e_1_3_4_3_2
e_1_3_4_2_2
e_1_3_4_9_2
e_1_3_4_8_2
e_1_3_4_7_2
e_1_3_4_41_2
e_1_3_4_6_2
e_1_3_4_40_2
e_1_3_4_5_2
e_1_3_4_4_2
e_1_3_4_22_2
e_1_3_4_45_2
e_1_3_4_23_2
e_1_3_4_44_2
e_1_3_4_43_2
Henderson HE (e_1_3_4_20_2) 1990; 7
e_1_3_4_21_2
e_1_3_4_42_2
e_1_3_4_26_2
e_1_3_4_27_2
e_1_3_4_24_2
e_1_3_4_25_2
e_1_3_4_46_2
Bradley WA (e_1_3_4_47_2) 1994; 736
e_1_3_4_28_2
e_1_3_4_30_2
e_1_3_4_11_2
e_1_3_4_34_2
e_1_3_4_12_2
e_1_3_4_33_2
e_1_3_4_32_2
e_1_3_4_10_2
e_1_3_4_31_2
e_1_3_4_15_2
e_1_3_4_38_2
e_1_3_4_16_2
e_1_3_4_37_2
e_1_3_4_13_2
e_1_3_4_36_2
e_1_3_4_14_2
e_1_3_4_35_2
e_1_3_4_19_2
e_1_3_4_17_2
e_1_3_4_18_2
e_1_3_4_39_2
Minnich A (e_1_3_4_29_2) 1998; 14
References_xml – ident: e_1_3_4_10_2
  doi: 10.1016/S0022-2275(20)37488-5
– ident: e_1_3_4_41_2
  doi: 10.1161/circulationaha.109.875807
– volume: 736
  start-page: 33
  year: 1994
  ident: e_1_3_4_47_2
  article-title: Triglyceride-rich lipoproteins and atherosclerosis: pathophysiological considerations
  publication-title: J Intern Med Suppl
– ident: e_1_3_4_36_2
  doi: 10.1016/0925-4439(92)90015-F
– ident: e_1_3_4_24_2
  doi: 10.1016/S0022-2275(20)41328-8
– volume: 7
  start-page: 511
  year: 1990
  ident: e_1_3_4_20_2
  article-title: Frameshift mutation in exon 3 of the lipoprotein lipase gene causes a premature stop codon and lipoprotein lipase deficiency
  publication-title: Mol Biol Med
– ident: e_1_3_4_21_2
  doi: 10.1126/science.3461561
– ident: e_1_3_4_34_2
  doi: 10.1016/S0022-2275(20)41340-9
– ident: e_1_3_4_46_2
  doi: 10.1016/0021-9150(94)90129-5
– ident: e_1_3_4_18_2
  doi: 10.1161/atvbaha.108.163931
– ident: e_1_3_4_28_2
  doi: 10.1042/bst0210506
– ident: e_1_3_4_7_2
  doi: 10.1073/pnas.95.23.13841
– ident: e_1_3_4_45_2
  doi: 10.1016/j.pharmthera.2003.10.001
– ident: e_1_3_4_42_2
  doi: 10.1172/JCI116074
– ident: e_1_3_4_8_2
  doi: 10.1042/bj3470357
– ident: e_1_3_4_14_2
  doi: 10.1093/aje/kwn235
– ident: e_1_3_4_17_2
  doi: 10.1161/01.CIR.94.12.3239
– ident: e_1_3_4_12_2
  doi: 10.1161/01.CIR.99.22.2901
– ident: e_1_3_4_2_2
  doi: 10.1172/JCI116081
– ident: e_1_3_4_5_2
  doi: 10.1194/jlr.M600292-JLR200
– ident: e_1_3_4_22_2
  doi: 10.1111/j.1365-2362.1980.tb02090.x
– ident: e_1_3_4_26_2
  doi: 10.1161/circulationaha.107.739888
– ident: e_1_3_4_35_2
  doi: 10.1111/j.1432-1033.1993.tb17747.x
– ident: e_1_3_4_15_2
  doi: 10.1194/jlr.R200015-JLR200
– ident: e_1_3_4_44_2
  doi: 10.2337/diacare.19.6.629
– ident: e_1_3_4_16_2
  doi: 10.1016/S0022-2275(20)41511-1
– ident: e_1_3_4_43_2
  doi: 10.1194/jlr.M400152-JLR200
– ident: e_1_3_4_3_2
  doi: 10.1073/pnas.74.11.4848
– ident: e_1_3_4_37_2
  doi: 10.1172/JCI111644
– ident: e_1_3_4_13_2
– ident: e_1_3_4_39_2
  doi: 10.1056/NEJM197806082982301
– ident: e_1_3_4_30_2
  doi: 10.1161/01.CIR.96.6.1737
– ident: e_1_3_4_32_2
  doi: 10.1016/S0021-9258(17)41822-9
– ident: e_1_3_4_33_2
  doi: 10.1016/S0021-9258(18)52459-5
– ident: e_1_3_4_4_2
  doi: 10.1056/NEJM198904203201607
– ident: e_1_3_4_40_2
  doi: 10.1016/S0006-291X(72)80149-9
– ident: e_1_3_4_38_2
  doi: 10.1172/JCI115229
– ident: e_1_3_4_23_2
  doi: 10.1073/pnas.81.6.1839
– ident: e_1_3_4_6_2
  doi: 10.1074/jbc.270.26.15747
– ident: e_1_3_4_9_2
  doi: 10.1161/01.atv.0000203512.01007.3d
– ident: e_1_3_4_27_2
  doi: 10.1016/j.cca.2005.12.038
– ident: e_1_3_4_11_2
  doi: 10.1126/science.3823907
– ident: e_1_3_4_19_2
  doi: 10.1172/JCI115114
– ident: e_1_3_4_25_2
  doi: 10.1161/01.ATV.13.5.629
– ident: e_1_3_4_31_2
  doi: 10.1016/S0022-2275(20)30146-2
– volume: 14
  start-page: 711
  year: 1998
  ident: e_1_3_4_29_2
  article-title: Lipoprotein lipase gene mutations in coronary artery disease
  publication-title: Can J Cardiol
SSID ssj0004220
Score 2.1253366
Snippet OBJECTIVE—We investigated the impact of lipoprotein lipase (LPL) gene mutations on apolipoprotein B (apoB)-100 metabolism. METHODS AND RESULTS—We studied 3...
We investigated the impact of lipoprotein lipase (LPL) gene mutations on apolipoprotein B (apoB)-100 metabolism. We studied 3 subjects with familial LPL...
We investigated the impact of lipoprotein lipase (LPL) gene mutations on apolipoprotein B (apoB)-100 metabolism.OBJECTIVEWe investigated the impact of...
SourceID pubmedcentral
proquest
pubmed
pascalfrancis
crossref
wolterskluwer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 459
SubjectTerms Adult
Alleles
Apolipoprotein B-100 - metabolism
Atherosclerosis (general aspects, experimental research)
Biological and medical sciences
Blood and lymphatic vessels
Cardiology. Vascular system
Case-Control Studies
Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
Female
Fundamental and applied biological sciences. Psychology
General aspects
Genotype
Heterozygote
Homozygote
Humans
Hypertriglyceridemia - etiology
Hypertriglyceridemia - metabolism
Lipoprotein Lipase - deficiency
Lipoprotein Lipase - genetics
Lipoproteins, IDL - metabolism
Lipoproteins, LDL - metabolism
Lipoproteins, VLDL - metabolism
Male
Medical sciences
Metabolic Diseases - complications
Metabolic Diseases - genetics
Metabolic Diseases - metabolism
Middle Aged
Mutation - genetics
Triglycerides - blood
Vertebrates: cardiovascular system
Title Apolipoprotein B-100–Containing Lipoprotein Metabolism in Subjects With Lipoprotein Lipase Gene Mutations
URI https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00043605-201202000-00038
https://www.ncbi.nlm.nih.gov/pubmed/22095987
https://www.proquest.com/docview/917157854
https://pubmed.ncbi.nlm.nih.gov/PMC4729373
Volume 32
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jj5swFLbSqVRVGlXdS5cRh94ipixmOzJVRlE7mVGrpMoNYTBq2gmMCmg0PfeH9z0bDDRRtwtiMcTK9-y3-Pl7hLzmPAexyXMDueUMGsJQTFInNWwYlGHi-CYVtQEX5958Rd-t3fVk8mOQtdTU7Dj9vndfyf-gCvcAV9wl-w_Iqo_CDTgHfOEICMPxrzCOsMTCVSm4FjbF9ARmO9PA5HNZ9mE6fLjlNeB9iTUx4Kpq2BeRxyHisMN2cA6KDSsr8-m2qQcBPcVVi_TOZQV9AQ0rKQqw2MKWdVcYi1cZri3LkwrmliJ9YFah4Tld9MHYj01VdWsgvK5u-pjsRUcoiXN2v4glA7fJtl1baSMXmAKiskDaydamBhKWSV205147Q_cRUOUoy-mWSjbxXTXgoRqIlp9OonmEWuEYLBMqSzGOObfPL-LT1dlZvJytl7fIbRucDayD8f7DgHPeFuSeqmfd1ivPerP7CyPz5hAAg5GWyxIp-3yY3VTcw-sS0ySqr2KXxMDWWd4n91onRY-kxD0gE148JHcWbRrGI7IZC57-q-Dpw4e94Olw1QmejoI3aicFT0fB05XgPSar09ny7dxoa3YYKQXP1bASRj0KZiV4qizJWJ7CHJE5LGNmmgWZ5_tZ6nGfZ26e-46bZKAwGNj8KfPDLAi484QcFGXBnxHdNRMWUnCAvTykieUyz8ysPHQd9HltxjRidX91nLaE9lhX5TIWjq1nxS086OXGEh6NTNU7V5LO5betj0YIqlds8PND0F0a0TtIY5iWca0tKXjZVHFo-RbySFGNPJUI9y_bGHsPfI34I-xVA2R8Hz8pNp8F8zsFV9jxoV_GSEpiuWc6Fuv6nukaONrMjjTCCZ7_uZsvyN1-iL4kB_W3hr8Cc7tmR2I0_AQNwdhy
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Apolipoprotein+B-100-containing+lipoprotein+metabolism+in+subjects+with+lipoprotein+lipase+gene+mutations&rft.jtitle=Arteriosclerosis%2C+thrombosis%2C+and+vascular+biology&rft.au=Ooi%2C+Esther+M+M&rft.au=Russell%2C+Betsy+S&rft.au=Olson%2C+Eric&rft.au=Sun%2C+Sam+Z&rft.date=2012-02-01&rft.issn=1524-4636&rft.eissn=1524-4636&rft.volume=32&rft.issue=2&rft.spage=459&rft_id=info:doi/10.1161%2FATVBAHA.111.238493&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1079-5642&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1079-5642&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1079-5642&client=summon